# Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

> **NCT02707562** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 26 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** GLPG1837 dose 1
- **DRUG:** GLPG1837 dose 2
- **DRUG:** GLPG1837 dose 3

## Key facts

- **NCT ID:** NCT02707562
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707562, "Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02707562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*